Exhibit 10.7


 


ASSIGNMENT AGREEMENT


 


This
Assignment Agreement (the “Agreement”) is made as of March 15, 2016 (the “Effective Date”), by and between
Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Tallikut”), and Accelerated Pharma,
Inc., a corporation organized under the laws of Delaware (“API”).


 


RECITALS


 


WHEREAS, Tallikut owns the right, title
and interest in and to all assets related to picoplatin including licensed rights to the AnorMED patents (the “Picoplatin
Assets”); and


 


WHEREAS API is desirous of acquiring the entire right,
title and interest in the same.


 


NOW, THEREFORE, in consideration of the
above recitals and the mutual covenants hereinafter set forth, API and Tallikut, intending to be legally bound, hereby agree as
follows:


 


		1.	Assignment. Tallikut agrees to sell, assign, transfer
and convey to API all of Tallikut’s right, title and interest in and to all of the following (collectively, the “Property
Rights”):



 


1.1. the worldwide rights,
title and interest in and to any and all trade names, trademark rights, trademarks and service marks (including any and all registrations,
licenses, applications and common law marks pertaining thereto), used in connection with the Picoplatin Assets, together with (a)
the goodwill of the Picoplatin Assets associated therewith and symbolized by same and (b) all common law rights therein and the
right to sue for past infringement of any and all of said trademarks (collectively, the “Trademarks”);


 


1.2. all worldwide rights,
title and interest of Tallikut in and to the designs, processes, drawings, schematics, copyrights and copyright applications, if
any, inventions, processes, know-how, trade secrets, patents (including any and all letter patents) patent applications (including
any Patent Cooperation Treaty patent applications and corresponding National patent applications) and other proprietary information
related to the Picoplatin Assets, including, without limitation, any registered copyrights,
patents and copyright and patent applications identified on Exhibit E, and in and to all substitutions, divisions, continuations,
continuationsin-part, reexaminations, extensions, renewals and reissues (as applicable) thereof, and including without limitation
of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well
as any and all choses in action and any and all claims and demands, both at law and in equity, that Tallikut has or may have for
damages or profits accrued or to accrue on account of the infringement of any patents, patent applications, letter patents, inventions,
improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by API, its successors and assigns,
as fully and entirely as the same would have been held and enjoyed by Tallikut if the assignment set forth herein had not occurred,
the full and complete right to file patent applications on the aforesaid inventions, improvements, discoveries and applications
in all countries of the world and the entire right, title and interest in and to any letter patent which may issue thereon in the
United States or in any country, and any and all renewals, revivals, reissues, reexaminations and extensions thereof, and any patents
of confirmation, registration and importation of the same (collectively, the “Intellectual Property Rights”);


 




    	 	 	 



     


    

 


1.3. all files, lists, publications,
and other records and data of Tallikut used in or relating to the Picoplatin Assets, regardless of the medium on which such information
is stored and maintained; and


 


1.4. all rights in and to any
governmental and private permits, licenses, and authorizations, to the extent assignable, used in or relating to the Picoplatin
Assets.


 


2.    Title
Passage. Upon the Effective Date, title to all of the Property Rights shall pass to API. Tallikut shall, upon API’s request,
execute any assignments, conveyances and/or bills of sale required to assign, transfer, set over, convey, assure and confirm unto
and vest in API, its successors and assigns, title to all of the Property Rights, as well as such other instruments of conveyance
as counsel for API may reasonably deem necessary to effect or evidence the transfers contemplated hereby.


 


3.    Purchase
Price. The aggregate consideration for the sale, transfer, conveyance and assignment of all the Property Rights to API shall
be $1 (the “Purchase Price”), receipt of which is hereby acknowledged.


 




    	 	2	 



     


    

 


IN WITNESS WHEREOF, the parties hereto have
duly executed this Assignment Agreement on the dates indicated below.


 


	TALLIKUT PHARMACEUTICALS, INC.	 	ACCELERATED PHARMA, INC.
	 	 	 
	By 	/s/ Fred Craves	 	By:	/s/ Michael Fonstein
	 	 	 	 	 
	Name:  	Fred Craves	 	Name:	Michael Fonstein
	 	 	 	 	 
	Title:  	Chairman of the Board	 	Title:  	Chief Executive Officer
	 	 	 	 	 
	Date:	3/15/16	 	Date:	3/15/16


 


State of _________________________________


County of________________________________


 


ACKNOWLEDGMENT


 


On this________day of March, in the year 2016,
before me, the undersigned, personally appeared Fred Craves, the Chairman of the Board of Tallikut Pharmaceuticals, Inc., a
corporation organized under the laws of Delaware, personally known to me or proved to me on the basis of satisfactory
evidence to be the person who executed the within Assignment Agreement in his or her capacity behalf of said corporation and
acknowledged to me that he or she executed the same for the purposes therein stated.


 


Seal:


 







Notary Public____________________________


My commission expires:







 


[SIGNATURE PAGE TO ASSIGNMENT AGREEMENT]


 




    	 	3	 



     


    

 


CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT





 



 





	State of California	
	 
	County of   San Francisco                                                   







 


	On	3/15/16	   before me,	M. A. Josephson
	 	Date	 	Here Insert Name and Title of the Officer


 


	Personally appeared 	/s/ Fred Craves
	 	Name(s) of Signer(s)
	 	 
	 	 


 





	 	who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.
	 
	I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
	 	 
	 	WITNESS my hand and official seal.
	 	 
	 	Signature	/s/ M. A. Josephson
	Place Notary Seal above	 	Signature of Notary Public







 


	OPTIONAL


 


Though the information below is not required
by law, it may prove valuable to persons relying on the document

and could prevent fraudulent removal and reattachment of this form to another document.


 


	Description of Attached Document


 


	Title or Type of Document:	 


 


	Document Date:	 	Number of Pages:	 


 


	Signer(s) Other Than Named Above:	 


 


Capacity(ies) Claimed by Signer(s


 


	Signer’s Name: ______________________	 	 	Signer’s Name: _________________________
	 ̈ Individual 	 	 	 ̈ Individual 
	 ̈ Corporate Officer — Title(s): ________	 	 	 ̈ Corporate Officer — Title(s): ____________
	 ̈ Partner —  ̈ Limited  ̈ General	 	 	 ̈ Partner —  ̈ Limited  ̈ General








	 ̈ Attorney in Fact 	 	 	 ̈ Attorney in Fact 	 
	 ̈ Trustee 	 ̈ Trustee 
	 ̈ Guardian or Conservator	 ̈ Guardian or Conservator
	 ̈ Other: _______________________	 ̈ Other: ____________________
	_______________________________	____________________________
	Signer Is Representing: ____________	Signer Is Representing: _________
	______________________________	____________________________
	______________________________	____________________________




 





 



 


©2007 National Notary Association• 9350 De Solo Ave., P.O.
Box 2402 *Chatsworth. CA 91313.2402 • www NationalNotary.org Item #5907 Reorder:Call Toll-Free 1-800-876-6827


 




    	 	4	 



     


    

 


EXHIBIT E


 


Intellectual Property Rights


 


	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	as applicable)	 	Date
    (as applicable)
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/857,067	 	11/6/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/877,515	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/927,347	 	5/3/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/931,309	 	5/22/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/969,441	 	8/31/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATTN TO TREAT SMALL CELL LUNG CANCER	 	US	 	12/508,392	 	7/23/2009
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/857,017	 	11/6/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/857,564	 	11/8/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/877,570	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATTN TO TREAT PROSTATE CANCER	 	US	 	60/889,179	 	2/9/2007


 




    	 	5	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/890,950	 	2/21/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/931,609 	 	5/24/2007 
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/952,440 	 	7/27/2007 
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	11/935,979	 	11/6/2007 
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/857,066	 	11/6/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/857/725	 	11/8/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/877,495	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/889,191	 	2/9/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/931,589	 	5/24/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/683,852	 	10/30/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	12/367,394	 	2/6/2009


 




    	 	6	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	121464,662	 	5/12/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	121465,563	 	5/13/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	12/508,372	 	7/23/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/U52010/34593	 	5/12/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	13/319,852	 	11/10/2011
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/889,201	 	2/912007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/889,675	 	2/13/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAT1N	 	US	 	60/984,156	 	10/31/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/989,020	 	11/19/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	PCT	 	PCT/U52008/00174 6	 	2/8/2009
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	12/536,311	 	8/5/2009


 




    	 	7	 



     


    

 


	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	ENCAPSULATED PICOPLATIN	 	AU	 	2008214199	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	BR	 	PI 0806362-1	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	CA	 	2,677,639	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	CN	 	200880011347.9	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAHN	 	EG	 	1200/2009	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAHN	 	EP	 	08725387.8	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	 	 	10102719.4	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	ID	 	W-00200902208	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	IL	 	200261	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	N	 	5257/CHENP/2009	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	JP	 	2009-549126	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	KR	 	10-2009-7018781	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	MX	 	MX/s/2009/008487	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	PH	 	1-2009-501520	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	RU	 	2009133447	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	UA	 	200909261	 	2/8/2008


 




    	 	8	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	ENCAPSULATED PICOPLATIN	 	VN	 	1-2009-01904	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORMS	 	US	 	60/889,171	 	2/9/2007
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	US	 	60/889,681	 	2/13/2007
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	PCT	 	PCT/US2008/00175 2	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	US	 	12/536,335	 	8/5/2009
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	AU	 	2008214202	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	BR	 	0806418-0	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	CA	 	2,677,640	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	CN	 	200880011357.2	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	EG	 	1201/2009	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	EP	 	08725393.6	 	2/8/2008


 




    	 	9	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	HK	 	10106157.4	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	ID	 	W-00200902207	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	IL	 	200262	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	IN	 	5256/CHENP/2009	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM*	 	JP	 	2009-549128	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM*	 	KR	 	10-2009-7018780	 	2/8/208
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	MX	 	MX/a/2009/008488	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	PH	 	1-2009-501521	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	RU	 	2009133446	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	UA	 	200909262	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM AND	 	VN	 	1-2009-01903	 	2/8/2008


 




    	 	10	 



     


    

 


	Patent	 	Country	 	
        Application No.

        or Registration

        No.

        (as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	PROCESS FOR  PREPARING THE  SAME*	 	 	 	 	 	 
	 	 	 	 	 	 	 
	STABILIZED INTRAVENOUS DOSAGE FORM	 	US	 	60/949,639	 	6/27/2007
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	US	 	60/950,033	 	7/16/2007
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	US	 	61/043,962	 	4/10/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	PCT	 	PCT/U S2008/008669	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	US	 	12/669,274	 	1/15/2010
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	CA	 	2,693,057	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	CN	 	200880103323.6	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	EP	 	08780206.2	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	I-1K	 	11101572.1	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	.1P	 	2010-517010	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	TW	 	097127053	 	7/16/2008
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,387	 	2/8/2008


 




    	 	11	 



     


    

 


	Patent	 	Country	 	
        Application No.

        or Registration

        No.

        (as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/U52009/00077 0	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	12/866,702	 	11/11/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	AU	 	2009210654	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	CA	 	2,715,348	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND 13EVACIZUMAB TO TREAT COLORECTAL CANCER	 	UN	 	200980109758.6	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	EP	 	09708527.8	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	HK	 	11109428.0	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	JP	 	2010-545883	 	2/6/2009


 




    	 	12	 



     


    

 


	Patent	 	Country	 	Application No.

or Registration

No.

(as applicable)	 	Application Filing

Date or Registration

Date (as applicable)
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,382	 	2/8/2008
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/US2009/00077 3	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	US	 	12/866,706	 	11/15/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	AU	 	2009210656	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	CA	 	2,715,353	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	CN	 	200980111015.2	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	EP	 	097083873	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	HK	 	111094253	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	JP	 	2010-545885	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,360	 	2/8/2008


 




    	 	13	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	PCT	 	PCT/US2009/00075 0	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER	 	US	 	12/866,710	 	11/10/2010
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	AU	 	2009210734	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	CA	 	2,715,329	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	CN	 	200980110139.9	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER	 	EP	 	09708292.9	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	HK	 	11109534J	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	JP	 	2010-545878	 	2/6/2009
	 	 	 	 	 	 	 
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	 	US	 	61/027,388	 	2/8/2008
	 	 	 	 	 	 	 
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	 	US	 	61/055/071	 	5/21/2008


 




    	 	14	 



     


    

 


	Patent	 	Country	 	
        Application No.

or Registration

No.

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	STABILIZED PICOPLATIN DOSAGE FORM	 	PCT	 	PCT/U52008/08076	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	US	 	12/635,517	 	12/10/2009
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	US	 	12/635,534	 	12/10/2009
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	US	 	12/781,599	 	5/17/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	PCT	 	PCT/US11/036855	 	5/17/2011
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	AU	 	2008295576	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	BR	 	P10811816-7	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	CA	 	2,691,115	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	CN	 	200880022248.0	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	EP	 	08828991.3	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	HK	 	10108170.3	 	6/27/2008


 




    	 	15	 



     


    

 


	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	STABILIZED PICOPLATIN DOSAGE FORM	 	ID	 	W-00201000277	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	ru	 	 	 	6/27/208
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	IN	 	7725/CHENP/2009	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	JP	 	20 10-5 14837	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	KR	 	10-2010-7001745	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	MX	 	MX/a12009/013835	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	RU	 	2010102096	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	TW	 	097124033	 	6/28/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	UA	 	201000817	 	6/28/2008
	 	 	 	 	 	 	 
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	 	US	 	61/169,679	 	4/15/2009
	 	 	 	 	 	 	 
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	 	US	 	61/170,487	 	4/17/2009
	 	 	 	 	 	 	 
	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	 	PCT	 	PCT/U52010/00735	 	3/11/2010


 




    	 	16	 



     


    

 


	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	 	US	 	13/264,343	 	10/13/2011
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	61/177,567	 	5/12/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	PCT	 	PCT/U52010/34591	 	5/12/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	13/319,647	 	11/9/2011
	 	 	 	 	 	 	 
	USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER	 	US	 	61/177,571	 	5/12/2009
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	US	 	61/186,526	 	6/12/2009
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	PCT	 	PCT/US2010/38348	 	6/11/2010
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	TW	 	099119171	 	6/11/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	US	 	61/311,169	 	3/5/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	US	 	61/345,442	 	5/17/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	PCT	 	PCT/U52011/02726 4	 	3/4/2011


 




    	 	17	 



     


    

 


	Patent	 	Country	 	
        Application No.

or Registration

No,

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	TW	 	100 1076 12	 	3/7/2011
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	US	 	61/345,451	 	5/17/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	US	 	61/346,777	 	5/20/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	PCT	 	PCT/1J52011/02726	 	3/4/2011
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	TW	 	100107621	 	3/7/2011
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	PCT	 	PCT/1J52008/00320	 	3110/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	US	 	12/531,010	 	9/11/2009
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	CA	 	2,681,015	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	CN	 	200880015910.X	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	EP	 	08726698.7	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	HK	 	10107956.5	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	IN	 	5948/DELNP/2009	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	JP	 	2009-553600	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	TW	 	97109125	 	3/14/2008


 




    	 	18	 



     


    

 


	Patent	 	Country	 	
        Application No.

or Registration

No.

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS	 	PCT	 	PCT/US2010/04535	 	8/12/2010
	 	 	 	 	 	 	 
	SYNTHESIS AND USE OF KINASE INHIBITORS	 	US	 	61/359,942	 	6/30/2010
	 	 	 	 	 	 	 
	SYNTHESIS AND USE OF KINASE INHIBITORS	 	PCT	 	PCT/US2011/04216	 	6/28/2011
	 	 	 	 	 	 	 
	ORAL FORMULATION OF 1UNASE INHIBITORS	 	US	 	61/359,694	 	6/29/2010
	 	 	 	 	 	 	 
	ORAL FORMULATION OF KINASE INHIBITORS	 	PCT	 	PCT/U52011/04216	 	6/28/2011


 




    	 	19